Treatment of migraine in Canada with naratriptan: A cost-effectiveness analysis

Headache

Volumn 41, Issue 5, 2001, Pages 456-464

  Caro, J Jaime ^a,d   Getsios, Denis ^b   Raggio, Gabriel ^a   Caro, Graciela ^b   Black, Libby ^c  

^a Caro Research   (United States)

^b Caro Research Institute   (Canada)

^c GLAXOSMITHKLINE   (United States)

^d CARO RESEARCH INSTITUTE   (United States)

Author keywords

Canada; Cost effectiveness; Migraine; Monte Carlo model; Naratriptan

Indexed keywords

NARATRIPTAN;

ADULT; ARTICLE; CANADA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MALE; MIGRAINE; PRIORITY JOURNAL; SYMPTOMATOLOGY; SYSTEM ANALYSIS;

CANADA; COST-BENEFIT ANALYSIS; HUMANS; INDOLES; MIGRAINE DISORDERS; PIPERIDINES; SEROTONIN AGONISTS; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 0035016240     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2001.01083.x     Document Type: Article

References (32)

1. O'Brien B, Goerec R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey, Int J Epidemiol. 1994;23:1020-1026.
2. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19:333-339.
3. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813-818.
4. Solomon GD. Quality of life assessment in patients with headache. Pharmacoeconomics. 1994;6:34-41.
5. Anonymous. Many migraineurs undiagnosed and untreated. Reuters Health. October 25, 1999.
6. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice [published correction appears in CMAJ. 1997;157:1354]. CMAJ. 1997;156:1273-1287.
7. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice [published correction appears in CMAJ. 1997;157:1354]. CMAJ. 1997;156:1273-1287.
8. Rozen TD, Swanson JW, Stang PE, McDonnell SK, Rocca WA. Increasing incidence of medically recognized migraine headache in a United States population. Neurology. 1999;53:1468-1473.
9. Peatfield RC. Migraine: which triptan? Hosp Med Lond. 1999;60:277-280.
10. Pauwels PJ, John GW. Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol. 1999;22:123-136.
11. Diamond S, Lyss H. Clinical and financial implications of migraine in a managed care setting. Drug Benefit Trends. 1999;11:55-57,61-65.
12. Dulli DA. Naratriptan: an alternative for migraine. Ann Pharmacother. 1999;33:704-711.
13. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A, on behalf of the Naratriptan S2WA3003 Study Group. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology. 1997;49:1485-1490.
14. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A, on behalf of the Naratriptan S2WA3001 Study Group. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache. 1997;37:640-645.
15. Bomhof MA, Heywood J, Pradalier A, Enahoro H, Winter P, Hassani H, on behalf of the Naratriptan Long-term Study Group. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Cephalalgia. 1998;18:33-37.
16. Dahlöf C, Winter P, Whitehouse H, Hassani H. Randomized, double-blind, placebo-controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine [abstract]. Neurology. 1997;48:A85.
17. Consumer Prices and Price Indexes. Ottawa: Statistics Canada; 1999.
18. Caro JJ, Caro G, Getsios D, Raggio G, Burrows M, Black L. The migraine ACE model: evaluating the impact on time lost and medical resource use. Headache. 2000;40:282-291.
19. Health Reports. Ottawa: Statistics Canada; 1999:10.
20. Labour Force Annual Averages 1996. Ottawa: Statistics Canada; 1996.
21. Households' Unpaid Work: Measurement and Valuation. Ottawa: Statistics Canada; 1995.
22. Von Korff M. Subcutaneous sumatriptan and its impact on quality of life, productivity and patient satisfaction: a multinational study. Pharmacoeconomics. 1997;11:1-51.
23. Caro G, Getsios D, Caro JJ, et al. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian Comparative Economic Analysis, Cephalalgia. In press.
24. Hospital Indicators 1993/94. Ottawa: Statistics Canada; 1996.
25. Jacobs P, Bachynsky J, Hall E. A Manual of Standard Costs for Pharamcoeconomic Studies in Canada: Feasibility Study. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1995.
26. Optenberg S, Jacobs P, Bay K, Barer DJ, Hall EM. Emergency care episodes: an economic profile. J Ambul Care Manage. 1995;18:1-12.
27. Earnings of Men and Women 1996. Ottawa: Statistics Canada; 1997.
28. Zyblock M. Individual Earnings Inequity and Polarization: An Exploration Into Population Sub-group Trends in Canada: 1981-1993. Applied Research Branch. Strategic Policy, Human Resources Development Canada; 1996. Working Paper W-96-8E.
29. Luciani R, Carter D, Mannix L, Hemphill M, Diamond M, Cady R. Prevention of migraine during prodrome with naratriptan. Cephalalgia. 2000;20:122-126.
30. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1997;13:1-77.
31. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1997;10:460-466.
32. Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature: a review. Int J Technol Assess Health Care. 1998; 14:799-808.